Flexion Therapeutics
196 articles with Flexion Therapeutics
-
Flexion Expands Supply Capacity For FX006 By Entering Into Agreement With Patheon
8/5/2015
-
Flexion Completes Enrollment In Phase III Clinical Trial With Lead Compound FX006 In Patients With Osteoarthritis Of The Knee
7/30/2015
-
Flexion' Final FX006 Data From Completed Phase IIb Dose-Ranging Trial Published In Journal Of Bone And Joint Surgery
6/4/2015
-
Flexion Reports First-Quarter 2015 Financial Results
5/8/2015
-
Flexion To Report First-Quarter 2015 Financial Results On May 7, 2015
5/1/2015
-
Flexion Awarded Approximately $2 Million From U.S. Department Of Defense To Conduct Clinical Trial Of FX006 In Military Personnel With Osteoarthritis Of The Knee
4/30/2015
-
Flexion To Present At 14th Annual Needham Healthcare Conference
4/8/2015
-
Flexion CEO Discusses Pipeline and Jobs
4/3/2015
-
Flexion Therapeutics Reports Year-End 2014 Financial Results
3/24/2015
-
Flexion Therapeutics To Report Year-End 2014 Earnings Results On March 23, 2015
3/17/2015
-
Flexion Therapeutics Announces Changes To Board Of Directors
3/9/2015
-
Flexion Therapeutics Completes Enrollment In Pivotal Phase 2b Confirmatory Clinical Trial With Lead Compound FX006
2/24/2015
-
Flexion Therapeutics To Present At RBC Capital Markets Healthcare Conference
2/17/2015
-
Flexion Therapeutics Initiates Phase 3 Clinical Trial Of FX006 In Patients With Osteoarthritis Of The Knee
2/3/2015
-
Flexion Therapeutics Announces Exercise Of Underwriters' Over-Allotment Option And Closing Of Public Offering Of Common Stock
12/17/2014
-
Flexion Therapeutics Announces Pricing Of Public Offering Of Common Stock
12/12/2014
-
Flexion Therapeutics Announces Public Offering Of Common Stock
12/9/2014
-
FDA Lifts Clinical Hold On Flexion Therapeutics's FX006 For Osteoarthritis Pain
12/3/2014
-
Flexion Therapeutics To Present At Stifel Healthcare Conference 2014
11/17/2014
-
Flexion Therapeutics Reports Third-Quarter 2014 Financial Results
11/14/2014